Research programme: anti-inflammatory therapeutics - Beactica/Centre for Drug Design and Discovery/VIB
Alternative Names: Small molecule anti-inflammatory therapeutics - Beactica/CD3/VIB; Small molecule anti-inflammatory therapeutics - Beactica/Centre for Drug Design and Discovery/VIBLatest Information Update: 28 Mar 2023
At a glance
- Originator Beactica; Centre for Drug Design and Discovery; VIB
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Inflammation in Belgium
- 28 Mar 2023 No recent reports of development identified for research development in Inflammation in Sweden
- 27 Feb 2019 Beactica enters into a research alliance with VIB and KU Leuven’s Centre for Drug Design and Discovery for anti inflammatory therapeutics